Avidas acquires rights to Crown dermatology products

DOYLESTOWN, Pa. A drug company that focuses on dermatology, women’s health and endocrinology announced Tuesday that it had acquired North American rights to several prescription and OTC skin medicines from Crown Laboratories.

Avidas Pharmaceuticals said the acquisition expanded its dermatology franchise and added products for chronic skin diseases such as scalp psoriasis and seborrheic dermatitis, disorders that affect more than 15 million people in the United States.

“We are very please to have concluded this transaction with Avidas and look forward to an enduring partnership,” Crown chief executive officer Jeff Beddard said in a statement. “We are committed to continuing to build on our tradition of high-quality product development focused on specialty needs.”

Login or Register to post a comment.